Topics

Startup stories Company stories Markets & events People & wealth Family offices

AI & automation

Business automation Industry AI Agents & tools Physical AI

Funding & fundraising Startups & growth Business & growth Acquisitions & ownership

People

All people Investors Angel investors Wealth Founders Boards Executives Leadership changes Get your profile

New Wealth

Explore New Wealth After a business sale Navigating an inheritance Employee equity payouts Large investment gains

Connections Startups Companies Investors Directory Library Get Featured

WatchlistSign in

Home
Companies
Gene Editing Tool Developer companies

Understand the business

Gene Editing Tool Developer companies

Explore companies classified in gene editing tool developer, with their latest reporting and business connections.

Discover startups Explore industries Request a company Tell your company’s story

Loading profiles…

About Branding Family Offices Articles Stock movers Opportunities List a Business Business Ideas Validate Founders to Watch Get Featured Pricing Business Terms T&C Privacy Refunds Contact

All publications RSS News RSS Guides RSS

Gene Editing Tool Developer Companies & Business Analysis - MoneyMakers

Search companies

Filters1 active

Business industryBusiness industry: broad category

Specific industry (optional)

Company typeOpen to opportunities

Opportunities reflect published company preferences. Funding includes investment and loans.

Showing 1–1 of 1 companies · Page 1 of 1

Editpep
Editpep develops nonviral CRISPR delivery technology for potential therapies, initially focused on the brain.
Gene Editing Tool Developer

Latest reporting

Stories about these companies

Published coverage connected to the companies in this selection.

Browse all reporting

Conceptual illustration for Editpep showing a molecular cluster and purple DNA helix beside a branching neuron-like cell.

Startups & growth· Analysis

Editpep develops a nonviral way to deliver CRISPR for brain therapies

Editpep is developing a nonviral way to deliver CRISPR machinery, with brain therapies as its first focus and licensing as a possible commercial route.

9 Nov 2026 · MoneyMakers